RxDoctor Payments DataLook up a doctor →

Joseph Te, MD

Hematology & Oncology · St George, UTNPI 1700946423

Payments from drug & device makers

$29,356in general payments, 2019–2025

Across 1,439 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Merck$2K
  • Genentech USA, Inc.$1K
  • Johnson & Johnson$1K
  • plus $15K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis138$5,165
AstraZeneca(2 entities)121$2,214
E.r. Squibb & Sons, L.L.C.107$1,682
Merck80$1,625
Genentech USA, Inc.70$1,429
Johnson & Johnson(2 entities)69$1,406
Pfizer100$1,305
Astellas Pharma US Inc36$1,159
Eisai Inc.51$875
Incyte Corporation43$864
Amgen58$857
Seagen Inc.48$815
Daiichi Sankyo Inc.39$708
Lilly USA, LLC37$614
Bristol Myers Squibb33$542
Takeda Pharmaceuticals U.S.A., Inc.24$541
Sanofi25$539
AbbVie28$532
Bayer30$493
Pharmacyclics LLC, An Abbvie Company23$454
Gilead(2 entities)19$403
EMD Serono, Inc.23$397
Exelixis Inc.18$294
Jazz Pharmaceuticals Inc.14$270
GSK14$262
Boehringer Ingelheim11$255
Regeneron Healthcare Solutions, Inc.12$253
Array Biopharma Inc20$240
Genmab U.S., Inc.9$225
Karyopharm Therapeutics Inc.11$196
Sobi, Inc6$190
Dendreon Pharmaceuticals LLC9$172
Puma Biotechnology, Inc.8$150
CSL Behring3$149
Blueprint Medicines Corporation5$118
Myovant Sciences Inc.6$109
Stemline Therapeutics Inc.5$102
AVEO Pharmaceuticals, Inc.1$100
Coherus Oncology, Inc.5$98
Tesaro, Inc.5$95
Sanofi-aventis U.S. LLC2$95
Agios Pharmaceuticals, Inc.5$92
Sumitomo Pharma America, Inc.4$91
Tersera Therapeutics LLC3$82
Deciphera Pharmaceuticals Inc.4$80
Rigel Pharmaceuticals, Inc.5$79
Geron Corporation3$71
Servier Pharmaceuticals LLC3$65
Pharmaessentia USA Corporation3$55
Amneal Pharmaceuticals LLC2$52
Heron Therapeutics, Inc.3$45
CTI Biopharma Corp.2$43
Celltrion USA Inc.1$37
ADC Therapeutics America, Inc.2$36
Helsinn Therapeutics (U.S.), Inc.2$34
G1 Therapeutics, Inc.2$32
Ipsen Biopharmaceuticals, Inc2$32
Tolmar Pharmaceuticals, Inc.2$32
Recordati_rare_diseases_inc.1$31
Dova Pharmaceuticals2$30

How this compares

$29,356 in reported general payments places this provider in the 55th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah →

Medicare billing

Part B allowed, 2024
$5,520,231
Medicare patients
1,189
Services billed
286,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in St George

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →